Treatment of sepsis and septic shock: Is there a light at the end of the tunnel?

Current Opinion in Anaesthesiology

Volumn 16, Issue 2, 2003, Pages 101-104

  Booke, Michael ^a   Westphal, Martin ^b  

^a Main Taunus Kreises GmbH   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Activated protein C; Antithrombin III; Corticosteroids; Hemofiltration; Insulin; Sepsis; Systemic inflammatory response syndrome

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; CORTICOSTEROID;

CLINICAL RESEARCH; CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNE DEFICIENCY; INFECTION; INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0037396785     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200304000-00001     Document Type: Review

References (28)

1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/ SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655.
2. Graf J, Doig GS, Cook DJ, et al. Randomized, controlled clinical trials in sepsis: has methodological quality improved over time? Crit Care Med 2002; 30:461-472.
3. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709. This multicenter, randomized controlled clinical trial provided the long awaited breakthrough in clinical sepsis research, showing a significant reduction in mortality. In the meantime, activated protein C is commercially available and is likely to become an integral part of sepsis-treatment.
4. Pastores M, Papdopoulos E, Van Den brink M, et al. Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C. Bone Marrow Transplant 2002; 30:131-134.
5. Warren BL, Eid A, Singer P, et al. High-dose antithrombin III in severe sepsis. JAMA 2001; 286:1869-1878. Another multicenter, randomized controlled clinical trial performed in septic patients. However, a reduction in mortality could not be achieved.
6. Rublee D, Opal SM, Schramm W, et al. Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial. Critical Care 2002; 6:349-356. This study showed that treatment during intensive care unit stay has an impact on quality of life after discharge.
7. DePalo V, Kessler C, Opal SM. Success or failure in phase III sepsis trials: comparison between the Drotrecogin Alfa (Activated) and Antithrombin III clinical trials. Advances in Sepsis 2001; 1:114-124. This paper compares the KyberSept trial with the PROWESS trial and analyses their different results.
8. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377. This study underlined the importance of instant treatment after the onset of sepsis.
9. Perla D, Marmorston J. Suprarenal cortical hormone and salt in the treatment of pneumonia and other severe infections. Endocrinology 1940; 27:367-374.
10. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23:1294-1303.
11. Cronin L, Cook DJ, Cadet J, et al. Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23:1430-1439.
12. Briegel J, Jochum M, Gippner-Steppert C, Thiel M. Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 2001; 12:S70-S74.
13. van Leeuwen HJ, van der Bruggen T, Van Asbeck S, Boereboom FTJ. Effect of corticosteroids on nuclear factor kappa B activation and hemodynamics in late septic shock. Crit Care Med 2001; 29:1074-1077.
14. Bäuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87:13-20.
15. Schroeder S, Wichers M, Klingmüller D, et al. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 2001; 29:310-316.
16. Tayek JA, Atienza VJ, Pituitary-adrenal axis function in systemic inflammatory response syndrome. Endocrine 1995; 3:315-318.
17. Briegel J, Schelling G, Haller M, et al. A comparison of the adrenocortical response during septic shock and after complete recovery. Intensive Care Med 1996; 22:894-899.
18. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to norepinephrine in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998; 46:589-597.
19. Oppert M, Reinicke A, Gräf KJ, et al. Plasma cortisol levels before and during "low-dose" hydrocortisone therapy and their relationship to hemodynamic improvement in patients with septic shock. Intensive Care Med 2000; 26:1747-1755.
20. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock. A prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723-732.
21. Bellissnat E, Annane D. Effect of hydrocortisone on phenylephrine: mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 2000; 68:293-303.
22. Briegel J. Hydrocortisone and the reduction of vasopressors in septic shock: therapy or only chart cosmetics? Intensive Care Med 2000; 26:1723-1726.
23. Bradley C. Steroids in sepsis: more effective than activated protein C? Intensive Crit Care Nurs 2001; 17:242-244.
24. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871. This was a multicenter, randomized controlled clinical trial performed in septic patients, showing a reduction in mortality in a subgroup of patients with relative adrenal insufficiency treated with low dose corticoids.
25. Reeves JH, Butt WW, Shann F, et al. Continuous plasma filtration in sepsis syndrome. Crit Care Med 1999; 27:2096-2104.
26. Kornecki A, Tauman R, Lubetzki R, Sivan Y. Continuous renal replacement therapy for non-renal indications: experience in children. Isr Med Assoc J 2002; 4:345-348.
27. Cole L, Bellomo R, Hart G, et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30:100-106.
28. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367. This study demonstrated the significant impact of strict normoglycemia on outcome of critically ill patients.